Which is the preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment? Full Text
Cardiovascular Diabetology,

Mallat SG – Clinical studies suggest that in CV high–risk patients and those with evidence of renal disease, the use of an ARB/CCB combination may be preferred to ARB/HCTZ combinations due to superior renoprotective and CV benefits and reduced metabolic side effects in patients with concomitant metabolic disorders. However, selection of the most appropriate antihypertensive combination should be dependent on careful review of the individual patient and appropriate consideration of drug pharmacology.

  • Hypertension is a major associated risk for organ damage and mortality, which is further heightened in patients with prior cardiovascular (CV) events, comorbid diabetes mellitus, microalbuminuria and renal impairment.
  • Given that most patients with hypertension require at least two antihypertensives to achieve blood pressure (BP) goals, identifying the most appropriate combination regimen based on individual risk factors and comorbidities is important for risk management.
  • Single–pill combinations (SPCs) containing two or more antihypertensive agents with complementary mechanisms of action offer potential advantages over free–drug combinations, including simplification of treatment regimens, convenience and reduced costs.
  • The improved adherence and convenience resulting from SPC use is recognised in updated hypertension guidelines.
  • Despite a wide choice of SPCs for hypertension treatment, clinical evidence from direct head–to–head comparisons to guide selection for individual patients is lacking.
  • However, in patients with evidence of renal disease or at greater risk of developing renal disease, such as those with diabetes mellitus, microalbuminuria and high–normal BP or overt hypertension, guidelines recommend renin–angiotensin system (RAS) blocker–based combination therapy due to superior renoprotective effects compared with other antihypertensive classes.
  • Furthermore, RAS inhibitors attenuate the oedema and renal hyperfiltration associated with calcium channel blocker (CCB) monotherapy, making them a good choice for combination therapy.
  • The occurrence of angiotensin–converting enzyme (ACE) inhibitor–induced cough supports the use of angiotensin II receptor blockers (ARBs) for RAS blockade rather than ACE inhibitors.
  • In this regard, ARB–based SPCs are available in combination with the diuretic, hydrochlorothiazide (HCTZ) or the calcium CCB, amlodipine.
  • Telmisartan, a long–acting ARB with preferential pharmacodynamic profile compared with several other ARBs, and the only ARB with an indication for the prevention of CV disease progression, is available in two SPC formulations, telmisartan/HCTZ and telmisartan/amlodipine.

Please login or register to follow this author.
► Click here to access Full Text, PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Ophthalmology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Ophthalmology Articles

1 Mini-monovision versus multifocal intraocular lens implantation Journal of Cataract & Refractive Surgery, October 8, 2014    Clinical Article

2 Original and generic latanoprost for the treatment of glaucoma and ocular hypertension: are they really the same? Clinical and Experimental Pharmacology and Physiology, October 29, 2014    Clinical Article

3 Ganciclovir ophthalmic gel 0.15% for the treatment of acute herpetic keratitis: background, effectiveness, tolerability, safety, and future applications Full Text Therapeutics and Clinical Risk Management, September 10, 2014    Free full text    Clinical Article

4 Latanoprost in the treatment of glaucoma Full Text Clinical Ophthalmology, October 2, 2014    Free full text    Review Article

5 Age-related cataract in men in the selenium and vitamin E cancer prevention trial eye endpoints study: A randomized clinical trial JAMA Ophthalmology, October 3, 2014    Evidence Based Medicine    Clinical Article

6 The ocular hypotensive effect of saffron extract in primary open angle glaucoma: A pilot study Full Text BMC Complementary and Alternative Medicine, October 22, 2014    Free full text    Clinical Article

7 Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group Ophthalmology, August 4, 2014    Clinical Article

8 A randomized control trial to evaluate the effect of adjuvant selective laser trabeculoplasty versus medication alone in primary open-angle glaucoma: Preliminary results Full Text Clinical Ophthalmology, October 14, 2014    Free full text    Clinical Article

9 Femtosecond laser versus manual clear corneal incision in cataract surgery Journal of Refractive Surgery, September 2, 2014    Clinical Article

10 Comparison of 3 silicone hydrogel bandage soft contact lenses for pain control after photorefractive keratectomy Journal of Cataract & Refractive Surgery, October 7, 2014    Clinical Article

11 Comparative analysis of the visual performance after cataract surgery with implantation of a bifocal or trifocal diffractive IOL Journal of Refractive Surgery, October 27, 2014    Clinical Article

12 Ocular itch relief with alcaftadine 0.25% versus olopatadine 0.2% in allergic conjunctivitis: pooled analysis of two multicenter randomized clinical trials Advances in Therapy, October 20, 2014    Clinical Article

13 The novel Rho kinase (ROCK) inhibitor K-115: A new candidate drug for neuroprotective treatment in glaucoma Investigative Ophthalmology & Visual Science, October 10, 2014    Clinical Article

14 Cataractogenic potential of quetiapine versus risperidone in the long-term treatment of patients with schizophrenia or schizoaffective disorder: A randomized, open-label, ophthalmologist-masked, flexible-dose, non-inferiority trial Journal of Psychopharmacology, October 23, 2014    Clinical Article

15 Diabetes, fasting glucose, and the risk of glaucoma: A meta-analysis Ophthalmology, October 28, 2014    Evidence Based Medicine

16 A novel antiproliferative drug coating for glaucoma drainage devices Journal of Glaucoma, October 15, 2014    Clinical Article

17 Nepafenac 0.1% plus dexamethasone 0.1% versus dexamethasone alone: Effect on macular swelling after cataract surgery Journal of Cataract & Refractive Surgery, September 8, 2014    Clinical Article

18 Closure technique for leaking wound resulting from thermal injury during phacoemulsification Journal of Cataract & Refractive Surgery, September 4, 2014    Clinical Article

19 Long-term results of up to 12 years of over 700 cases of viscocanalostomy for open-angle glaucoma Acta Ophthalmologica, October 21, 2014    Clinical Article

20 Implementation of the posterior chamber intraocular lens intrascleral haptic fixation technique (glued intraocular lens) in a United States practice: Outcomes and insights Journal of Cataract & Refractive Surgery, October 30, 2014    Clinical Article

Indexed Journals in Ophthalmology: American Journal of Ophthalmology, Retina, Eye, Corneamore